ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Schrödinger and WuXi launch drug discovery company

by Michael McCoy
November 2, 2018 | APPEARED IN VOLUME 96, ISSUE 44

 

The computational chemistry firm Schrödinger has teamed up with the drug services provider WuXi AppTec to launch a new firm, Faxian Therapeutics. Headquartered in New York City, Faxian will use Schrödinger’s computational platform and WuXi’s drug design and synthesis services to tackle unmet health care needs. Schrödinger earlier helped found Nimbus Therapeutics and Morphic Therapeutic.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment